is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history
Figure 7, Figure 8 and Figure 9 present the results of their studies using water, ethanol, and methanol extracts
Figure 2 Effect of Empagliflozin on the Pharmacokinetics of Various Medications as Displayed as 90% Confidence Interval of Geometric Mean AUC and Cmax Ratios [reference lines indicate 100% (80% - 125%)] aempagliflozin, 50 mg, once daily
Zou W., et al
However, other options are available for people living with type 2 diabetes, including GLP-1 agonists, which are primarily available in injectable form